Progress in allergy signal research on mast cells: regulation of allergic airway inflammation through toll-like receptor 4-mediated modification of mast cell function.

Department of Immunology, Graduate School of Medicine, Chiba University, Japan.
Journal of Pharmacological Sciences (Impact Factor: 2.15). 04/2008; 106(3):332-5. DOI: 10.1254/jphs.FM0070202
Source: PubMed

ABSTRACT In a mouse experimental asthma model, the administration of bacterial lipopolysaccharide (LPS), particularly at low doses, enhances the levels of ovalbumin (OVA)-induced eosinophilic airway inflammation. In an effort to clarify the cellular and molecular basis for the LPS effect, we demonstrate that the OVA-induced eosinophilic inflammation in the lung is dramatically increased by administration of LPS at the priming phase in wild-type mice, whereas such an increase was not observed in mast cell deficient mice. Adoptive transfer of bone marrow-derived mast cells (BMMC) from wild type but not from Toll-like receptor 4 (TLR4)-deficient mice restored the increased eosinophilic inflammation in mast cell-deficient mice. Moreover, in vitro analysis revealed that treatment of BMMC with LPS resulted in sustained up-regulation of GATA1 expression and increased production of Th2 cytokines (IL-4, IL-5, and IL-13) upon restimulation. Thus, mast cells appear to control allergic airway inflammation after their activation and modulation through TLR4-mediated induction of GATA1 proteins and subsequent increase in Th2 cytokine production.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The cytosolic Nucleotide Oligomerization Domain (NOD)-like receptors NOD-1 and NOD-2 are important contributors to the intracellular recognition of pathogens including Chlamydophila pneumoniae, but little is known about their influence on allergen-induced airway inflammation. In BALB/c mice, we observed that infection with C. pneumoniae prior to systemic sensitization with ovalbumin (OVA) and local OVA airway exposure diminished airway hyperresponsiveness. Thus, the impact of NOD1 agonist FK156 and NOD2 agonist muramyl dipeptide (MDP) given 6 hours prior to each sensitization or airway challenge was evaluated regarding airway hyperresponsiveness (AHR), OVA-specific plasma immunoglobulins, bronchoalveolar lavage fluid (BALF) differentials and cytokines. Further, spleen dendritic cells (DCs) of FK156-treated mice were isolated and cocultured with OVA-specific T cells isolated from DO11.10 mice, and T cell proliferation was quantified subsequent to OVA restimulation. Additionally, T cell proliferation was investigated in vivo in lungs and lymph nodes of FK156-treated and OVA-exposed DO11.10 mice. FK156 but not MDP reduced AHR and pulmonary eosinophilic infiltration, if given prior to OVA sensitization or challenge, while Th2 cytokines were not diminished. DCs from FK156-treated mice evoked less OVA-specific T cell proliferation as compared to solvent-treated controls. Similarly, antigen-specific T cell activation in lung tissue was diminished after FK156 treatment. We conclude that NOD1 activation reduced AHR in allergen-induced lung inflammation, which was accompanied by a reduction of allergen-specific T cell proliferation.
    American Journal of Respiratory Cell and Molecular Biology 11/2013; · 4.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Toll-like receptors (TLR) are key pattern recognition receptors in the innate immune system. The TLR-mediated immune response against pathogens is usually protective however inappropriate TLR activation may lead to excessive tissue damage. It is well recognised that TLRs respond to a variety of endogenous as well as exogenous ligands. By responding to endogenous ligands that are exposed during cellular damage, TLRs have been implicated in a range of pathological conditions associated with cardiovascular dysfunction. Increasing knowledge on the mechanisms involved in TLR signalling has encouraged the exploration of therapeutic pharmacological modulation of TLR activation in conditions such as atherosclerosis, ischaemic heart disease, heart failure and ischaemic reperfusion injury. The aim of this review is to explore the translational potentials of TLR modification in cardiovascular dysfunction, where these agents have been studied.
    Vascular Pharmacology 10/2012; · 3.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mast cells play a critical role during the development of an allergic response. Upon activation by an antigen and IgE, via FcεRI receptors, mast cells release histamine and other mediators that initiate and propagate immediate hypersensitivity reactions. Mast cells also secrete cytokines that regulate the immune responses. In this way, inhibitors of mast cell activity could work as promising therapeutics for allergic disorders. In the present work, we investigated the capacity of pyridovericin, a natural product isolated from the entomopathogenic fungus Beauveria bassiana, to inhibit mast cell degranulation and cytokine secretion. It was found that pyridovericin strongly decreased the release of β-hexosaminidase, a marker for mast cell degranulation, when mast cells were stimulated by both FcεRI-dependent and independent pathways. In addition, pyridovericin strongly abrogated secretion of interleukin-4. Pyridovericin-mediated suppression of stimulated increase in intracellular Ca(2+) levels, a crucial signal for mounting of both degranulation and cytokine production responses, was ascribed as one of the inhibition targets of pyridovericin. Those initial studies identify pyridovericin as a potential new candidate for the development of new anti-allergic drugs.
    International immunopharmacology 02/2013; · 2.21 Impact Factor